PUBLISHER: TechNavio | PRODUCT CODE: 1559247
PUBLISHER: TechNavio | PRODUCT CODE: 1559247
Chronic Obstructive Pulmonary Disease Drugs Market 2024-2028
The chronic obstructive pulmonary disease drugs market is forecasted to grow by USD 7193.4 mn during 2023-2028, accelerating at a CAGR of 6.24% during the forecast period. The report on the chronic obstructive pulmonary disease drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of COPD, strong pipeline and new drug approvals, and growing demand for fixed-dose combinations.
Market Scope | |
---|---|
Base Year | 2024 |
End Year | 2028 |
Series Year | 2024-2028 |
Growth Momentum | Accelerate |
YOY 2024 | 5.49% |
CAGR | 6.24% |
Incremental Value | $7193.4 mn |
Technavio's chronic obstructive pulmonary disease drugs market is segmented as below:
By Product
By Distribution Channel
By Geographical Landscape
This study identifies the expanding research in curative approaches as one of the prime reasons driving the chronic obstructive pulmonary disease drugs market growth during the next few years. Also, advances in drug delivery devices and growing use of e-cigarettes and other products for people to quit smoking will lead to sizable demand in the market.
The report on the chronic obstructive pulmonary disease drugs market covers the following areas:
The vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading chronic obstructive pulmonary disease drugs market vendors that include AstraZeneca PLC, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., CHIESI Farmaceutici SpA, Cipla Inc., Exela Pharma Sciences LLC, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Innoviva, Inc., Lupin Ltd., Merck and Co. Inc., Mundipharma International Ltd., Novartis AG, Philip Morris International Inc., SHIONOGI Co. Ltd., Sumitomo Pharma Co. Ltd., Teva Pharmaceutical Industries Ltd., Theravance Biopharma Inc., Vertex Pharmaceuticals Inc., and Viatris Inc.. Also, the chronic obstructive pulmonary disease drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Exhibits: